ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0143

High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome

Yuzhou Gan1, Srilakshmi Yalavarthi2, Yiran Shen1, Cyrus Sarosh3, Xiangjun Liu4, Ajay Tambralli1, Jacqueline Madison1, Yu (Ray) Zuo1 and Jason S. Knight1, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, 3University of Michigan, Temperance, MI, 4Peking University, Beijing, Beijing, China

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, B-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the presence of pathogenic antiphospholipid antibodies (aPL) in the setting of venous or arterial thrombosis, pregnancy morbidity, and other morbid manifestations. B cells are central to APS pathogenesis through their role in aPL production. However, despite their pathogenic importance, the phenotypic and functional characteristics of circulating B cells in APS remain incompletely understood. In this study, we applied high-dimensional spectral flow cytometry to comprehensively characterize the activation profiles of circulating B cells in patients with APS.

Methods:

Methods: We developed a 26-color spectral flow cytometry panel to deeply characterize circulating B cell subsets and their activation states in patients with APS. The panel was designed based on established literature and included markers for B cell development, activation, memory, homing, and regulatory phenotypes. Peripheral blood mononuclear cells (PBMCs) were isolated from APS patients (n=37) fulfilling the 2023 ACR/EULAR APS classification criteria and age- and sex-matched healthy donors (n=16). Samples were stained and analyzed using a 5-laser Cytek Aurora spectral flow cytometer. Manual gating was performed using FlowJo software to define major B cell subsets, including naïve, transitional, memory, double-negative, and plasmablast populations. Activation markers such as CD86, CD95, CD69, and HLA-DR were assessed across subsets. Statistical analyses were conducted using SPSS to compare APS patients with healthy controls, with significance defined as p < 0.05.

Results:

Results: Among the patients, 25 (67.6%) were diagnosed with primary APS, while 12 (32.4%) had APS associated with systemic lupus erythematosus (SLE). Gating strategies were shown in Fig. 1. Compared with healthy controls, patients with APS exhibited an increased proportion of B1a cells (CD5+CD43+) (0.30% of CD19+CD20+B cells [0.15, 0.44] vs. 0.14 [0.08, 0.22], p=0.010) and unswitched memory B cells (CD27+IgD+IgM+) (30.52% of CD19+CD20+B cells [21.68, 36.79] vs. 12.19 [9.59, 17.58], p< 0.001). In contrast, the proportion of naïve B cells (CD27-IgD+IgM+) was significantly reduced in APS patients (46.21% of B cells [42.34, 58.44] vs. 63.01 [57.51, 72.64], p< 0.001) (Fig. 2A). Moreover, the expression of the key checkpoint regulator PD-1 was reduced on transitional B1 cells (CD10hiIgDhiCD24hiCD38hi) and unswitched memory B cells in APS patients (Fig. 2B-C).

Conclusion: High-dimensional profiling of circulating B cells in APS patients reveals distinct alterations in subset distribution and activation states, including increased B1a and unswitched memory B cells and reduced naïve B cells, alongside diminished PD-1 expression on key populations. These results provide novel insights into B cell dysregulation in APS and raise the possibility that augmenting PD-1 signaling or modulating specific B cell subsets could represent future therapeutic strategies for this complex autoimmune disorder.

Supporting image 1Figure 1. Gating strategies of peripheral B cells from PBMCs.

Supporting image 2Figure 2. Altered proportions of B cell subsets and reduced PD-1 expression on unswitched memory and transitional B1 cells in APS patients.

(A) Heatmap showing the relative percentages (Z-score normalized) of B cell subsets in peripheral blood from patients with antiphospholipid syndrome (APS, n = 37) and healthy controls (HC, n = 16). Subsets include transitional B cells (TrB, TrB1–TrB3), memory B cells (MoB, switched and unswitched), antibody-secreting cells, naïve B cells, double-negative B cells (DN, DN1-DN3), and B1 cells (B1, B1a).

(B) Median fluorescence intensity (MFI) of PD-1 on unswitched memory B cells is significantly lower for APS patients versus HCs.

(C) PD-1 MFI on transitional B1 cells is also reduced in APS patients.

Supporting image 3Table 1. Baseline Demographic Characteristics of APS Patients and Healthy Controls


Disclosures: Y. Gan: None; S. Yalavarthi: None; Y. Shen: None; C. Sarosh: None; X. Liu: None; A. Tambralli: None; J. Madison: None; Y. Zuo: None; J. Knight: BioCryst, 2, Ouro Medicines, 2, Roche, 2, Roivant Sciences, 2, Visterra, 2.

To cite this abstract in AMA style:

Gan Y, Yalavarthi S, Shen Y, Sarosh C, Liu X, Tambralli A, Madison J, Zuo Y, Knight J. High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/high-dimensional-spectral-flow-cytometry-reveals-a-unique-distribution-of-circulating-b-cells-in-patients-with-antiphospholipid-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-dimensional-spectral-flow-cytometry-reveals-a-unique-distribution-of-circulating-b-cells-in-patients-with-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology